Holen Sie sich die Stockscreener-App
16.40
1.14%
0.19
Handel nachbörslich:
16.40
Schlusskurs vom Vortag:
$16.21
Offen:
$16.11
24-Stunden-Volumen:
5.07M
Relative Volume:
0.81
Marktkapitalisierung:
$11.20B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.9027
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+1.71%
1M Leistung:
+16.44%
6M Leistung:
+60.89%
1J Leistung:
+38.47%
1-Tages-Spanne:
$16.00
$16.78
1-Wochen-Bereich:
$15.90
$16.78
52-Wochen-Spanne:
$8.73
$16.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
16.40 | 11.07B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
A Look at Roivant Sciences’s Valuation Following Positive Phase 3 Result for Brepocitinib - Sahm
Roivant Sciences Ltd. stock prediction for this weekTrade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
Using Ichimoku Cloud for Roivant Sciences Ltd. technicalsPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
Top chart patterns to watch in Roivant Sciences Ltd.Trade Performance Summary & Community Verified Watchlist Alerts - newser.com
Evaluating Roivant Sciences Ltd. with trendline analysisQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Key metrics from Roivant Sciences Ltd.’s quarterly dataQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
What MACD and RSI say about Roivant Sciences Ltd.Trade Entry Summary & Weekly Watchlist of Top Performers - newser.com
How sentiment analysis helps forecast Roivant Sciences Ltd.Market Trend Report & Fast Moving Stock Trade Plans - newser.com
Using Bollinger Bands to evaluate Roivant Sciences Ltd.July 2025 Trends & Community Consensus Picks - newser.com
Is a relief rally coming for Roivant Sciences Ltd. holders2025 Bull vs Bear & Daily Oversold Bounce Ideas - newser.com
Combining machine learning predictions for Roivant Sciences Ltd.July 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Price action breakdown for Roivant Sciences Ltd.2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Will earnings trigger a reversal in Roivant Sciences Ltd.Weekly Market Summary & Safe Entry Zone Identification - newser.com
Eric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
What earnings revisions data tells us about Roivant Sciences Ltd.Bear Alert & Comprehensive Market Scan Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV) - MarketBeat
Can Roivant Sciences Ltd. stock deliver consistent earnings growthPortfolio Value Report & Growth Focused Entry Reports - newser.com
Roivant Sciences Hits New 52-Week High at $16.19, Up 52.84% - Markets Mojo
Roivant Sciences Hits New 52-Week High at $16.79, Surges 53.69% - Markets Mojo
Roivant Sciences’ president Venker sells $10.7m in shares - Investing.com
Valeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Rises on Nasdaq Composite with Strong Momentum - Kalkine Media
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighShould You Buy? - MarketBeat
Can you recover from losses in Roivant Sciences Ltd.2025 Price Action Summary & High Return Trade Guides - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockWeekly Trading Summary & Community Driven Trade Alerts - newser.com
Will Roivant Sciences Ltd. (87S) stock outperform value peersRisk Management & Consistent Profit Alerts - newser.com
Why Roivant Sciences (ROIV) Is Up 6.6% After Positive Phase 3 Brepocitinib Results and SEC Filing - simplywall.st
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsTrade Risk Report & Fast Entry High Yield Stock Tips - newser.com
Will Roivant Sciences Ltd. continue its uptrendWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Pattern recognition hints at Roivant Sciences Ltd. upsideMarket Growth Report & Safe Capital Growth Tips - newser.com
Why retail investors pile into Roivant Sciences Ltd. stock2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Is Roivant Sciences Ltd. stock reversal real or fakeM&A Rumor & High Win Rate Trade Tips - newser.com
Can Roivant Sciences Ltd. (87S) stock double in coming yearsJuly 2025 Breakouts & Fast Entry Momentum Alerts - newser.com
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints - Insider Monkey
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades - Yahoo Finance
Elevate Capital Advisors LLC Sells 61,368 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) files mixed shelf - StreetInsider
Roivant Sciences (ROIV): Assessing Valuation Following Positive Phase 3 Results and Analyst Optimism - simplywall.st
Roivant Sciences Ltd. $ROIV Shares Purchased by GAMMA Investing LLC - Defense World
Fifth Third Bancorp Sells 1,829 Shares of Roivant Sciences Ltd. $ROIV - Defense World
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):